Danaher Co. (NYSE:DHR – Free Report) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Danaher in a research report issued on Tuesday, March 25th. Zacks Research analyst R. Department now forecasts that the conglomerate will post earnings per share of $1.61 for the quarter, down from their prior estimate of $1.62. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s Q2 2025 earnings at $1.76 EPS, Q3 2025 earnings at $1.85 EPS, FY2025 earnings at $7.59 EPS, Q1 2026 earnings at $1.84 EPS and FY2026 earnings at $8.50 EPS.
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business earned $2.09 earnings per share.
Check Out Our Latest Stock Analysis on Danaher
Danaher Price Performance
NYSE:DHR opened at $210.15 on Thursday. The stock’s 50-day simple moving average is $215.86 and its 200 day simple moving average is $237.56. Danaher has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market cap of $150.19 billion, a P/E ratio of 39.80, a P/E/G ratio of 2.66 and a beta of 0.82.
Hedge Funds Weigh In On Danaher
Several institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Fire Capital Management LLC acquired a new stake in shares of Danaher during the 4th quarter valued at $823,000. DSG Capital Advisors LLC acquired a new stake in shares of Danaher during the fourth quarter valued at about $802,000. Chancellor Financial Group WB LP bought a new stake in shares of Danaher during the fourth quarter worth about $657,000. 111 Capital acquired a new position in shares of Danaher in the fourth quarter valued at approximately $1,734,000. Finally, Thoma Capital Management LLC bought a new position in Danaher in the 4th quarter valued at approximately $618,000. Institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by company insiders.
Danaher Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Find and Profitably Trade Stocks at 52-Week Lows
- Energy Transfer: Powering Data With Dividends and Diversification
- 3 Small Caps With Big Return Potential
- Qualcomm Stock Is Coiling for a Breakout
- How Can Investors Benefit From After-Hours Trading
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.